Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] traded at a high on 04/30/21, posting a 17.91 gain after which it closed the day’ session at $2.37. The company report on March 30, 2021 that Sonnet BioTherapeutics Provides 2021 Business Update.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced a business update on its ongoing programs.
“Last year we continued execution across our pipeline, and I am excited to share an update on our ongoing activities,” commented Pankaj Mohan, Ph.D., Founder and CEO. “This year we expect to be in the clinic with multiple programs, which we believe is an important milestone for patients.”.
The results of the trading session contributed to over 5011621 shares changing hands. Over the past one week, the price volatility of Sonnet BioTherapeutics Holdings Inc. stands at 9.47% while the volatility over the past one month is 6.61%.
The market cap for SONN stock reached $35.29 million, with 17.56 million shares outstanding and 15.34 million shares in the current float. Compared to the average trading volume of 1.03M shares, SONN reached a trading volume of 5011621 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sonnet BioTherapeutics Holdings Inc. [SONN]?
The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc. is set at 0.16, with the Price to Sales ratio for SONN stock in the period of the last 12 months amounting to 6.19.
How has SONN stock performed recently?
Sonnet BioTherapeutics Holdings Inc. [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.32. With this latest performance, SONN shares gained by 5.33% in over the last four-week period, additionally sinking by -9.20% over the last 6 months – not to mention a drop of -54.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 58.60, with the RSI for the last a single of trading hit 66.18, and the three-weeks RSI is set at 54.17 for Sonnet BioTherapeutics Holdings Inc. [SONN]. The present Moving Average for the last 50 days of trading for this stock 2.29, while it was recorded at 2.13 for the last single week of trading, and 2.60 for the last 200 days.
Sonnet BioTherapeutics Holdings Inc. [SONN]: Deeper insight into the fundamentals
Return on Total Capital for SONN is now -137.95, given the latest momentum, and Return on Invested Capital for the company is -328.93. When it comes to the capital structure of this company, Sonnet BioTherapeutics Holdings Inc. [SONN] has a Total Debt to Total Equity ratio set at 11.70. Additionally, SONN Total Debt to Total Capital is recorded at 10.47, with Total Debt to Total Assets ending up at 4.42. Long-Term Debt to Equity for the company is recorded at 8.28, with the Long-Term Debt to Total Capital now at 7.41.
Reflecting on the efficiency of the workforce at the company, Sonnet BioTherapeutics Holdings Inc. [SONN] managed to generate an average of -$2,696,124 per employee.Sonnet BioTherapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 0.50.
Insider trade positions for Sonnet BioTherapeutics Holdings Inc. [SONN]
There are presently around $1 million, or 2.70% of SONN stock, in the hands of institutional investors. The top three institutional holders of SONN stocks are: BLACKROCK INC. with ownership of 246,555, which is approximately 2.454% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 135,963 shares of the stock with an approximate value of $0.32 million in SONN stocks shares; and ADVISORY SERVICES NETWORK, LLC, currently with $58000.0 in SONN stock with ownership of nearly 32.291% of the company’s market capitalization.
Positions in Sonnet BioTherapeutics Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 9 institutional holders increased their position in Sonnet BioTherapeutics Holdings Inc. [NASDAQ:SONN] by around 108,952 shares. Additionally, 9 investors decreased positions by around 50,089 shares, while 4 investors held positions by with 299,503 shares. The mentioned changes placed institutional holdings at 458,544 shares, according to the latest SEC report filing. SONN stock had 5 new institutional investments in for a total of 48,921 shares, while 7 institutional investors sold positions of 50,007 shares during the same period.